Chonnam Med J.  2016 Sep;52(3):159-172. 10.4068/cmj.2016.52.3.159.

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update

Affiliations
  • 1Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea. pae@catholic.ac.kr
  • 2International Health Care Center, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
  • 3Department of Psychiatry, College of Medicine, Korea University, Korea.
  • 4Department of Psychiatry and Behavioural Sciences, Duke University Medical Center, Durham, NC, USA.
  • 5Global Medical Education, New York, NY, USA.

Abstract

Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has been increasingly recognized as an important treatment option. The authors have previously provided a comprehensive review of SGAs for the treatment of MDD in 2013. Since then, numerous additional clinical trials have been conducted to investigate diverse issues regarding the utility of SGAs in MDD. Moreover, a new SGA, brexpiprazole, was recently approved by the Food and Drug Administration in July 2015 for the treatment of MDD as an augmentation agent to antidepressants. Thus, the aim of this study was to provide a concise update of all the available SGAs for the treatment of MDD, in particular on the additional clinical trials which have been published since 2013.

Keyword

Antidepressive Agents; Depressive Disorder; Clinical Trial; Antipsychotic Agents; Depressive Disorder, Treatment-Resistant

MeSH Terms

Antidepressive Agents
Antipsychotic Agents*
Depressive Disorder
Depressive Disorder, Major*
Depressive Disorder, Treatment-Resistant
Humans
United States Food and Drug Administration
Antidepressive Agents
Antipsychotic Agents

Figure

  • FIG. 1 Evolution of antidepressant. MAOI: monoamine oxidase inhibitors, NDRI: norepinephrine-dopamine reuptake inhibitor (NDRI), Rc: receptors, RI: reuptake inhibitor, SNRI: norepinephrine reuptake inhibitor, SSRI: selective serotonin reuptake inhibitors, TCA: tricyclic antidepressants.


Reference

1. Pae CU, Tharwani H, Marks DM, Masand PS, Patkar AA. Atypical depression: a comprehensive review. CNS Drugs. 2009; 23:1023–1037.
2. Kulkarni SK, Dhir A. Current investigational drugs for major depression. Expert Opin Investig Drugs. 2009; 18:767–788.
Article
3. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163:1905–1917.
Article
4. Wang SM, Han C, Pae CU. Criticisms of drugs in early development for the treatment of depression: what can be improved? Expert Opin Investig Drugs. 2015; 24:445–453.
Article
5. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001; 158:131–134.
Article
6. Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia IM, et al. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 2009; 50:78–86.
Article
7. Kang HJ, Bae KY, Kim SW, Shin IS, Hong YJ, Ahn Y, et al. Associations between serotonergic genes and escitalopram treatment responses in patients with depressive disorder and acute coronary syndrome: The EsDEPACS study. Psychiatry Investig. 2016; 13:157–160.
Article
8. Jeon SW, Han C, Lee J, Lim J, Jeong HG, Park MH, et al. Perspectives on the happiness of community-dwelling elderly in Korea. Psychiatry Investig. 2016; 13:50–57.
Article
9. Park YM. Relationship between serotonergic dysfunction based on loudness dependence of auditory-evoked potentials and suicide in patients with major depressive disorder. Psychiatry Investig. 2015; 12:421–424.
Article
10. Gao L, Gao Y, Xu E, Xie J. Microarray Analysis of the major depressive disorder mRNA profile data. Psychiatry Investig. 2015; 12:388–396.
Article
11. Lee J, Joo EJ, Lim HJ, Park JM, Lee KY, Park A, et al. Proteomic analysis of serum from patients with major depressive disorder to compare their depressive and remission statuses. Psychiatry Investig. 2015; 12:249–259.
Article
12. Khosravi M, Sotoudeh G, Majdzadeh R, Nejati S, Darabi S, Raisi F, et al. Healthy and unhealthy dietary patterns are related to depression: a case-control study. Psychiatry Investig. 2015; 12:434–442.
Article
13. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999; 60:256–259.
Article
14. Han C, Wang SM, Kato M, Lee SJ, Patkar AA, Masand PS, et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother. 2013; 13:851–870.
Article
15. U.S. FDA Approves Otsuka and Lundbeck's REXULTI® (Brexpiprazole) as Adjunctive Treatment for Adults with Major Depressive Disor [Internet]. Rockville: Otsuka America Pharmaceutical, Inc.;c2016. cited 2016 Mar 1. Available from: http://www.otsuka-us.com/newsroom/Pages/NewsArticle.aspx?ItemId=13/.
16. Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014; 350:605–614.
Article
17. Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015; 76:1232–1240.
Article
18. Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015; 76:1224–1231.
Article
19. Pae CU, Sohi MS, Seo HJ, Serretti A, Patkar AA, Steffens DC, et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34:1165–1173.
Article
20. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009; 14:197–206.
Article
21. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007; 68:843–853.
Article
22. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008; 28:156–165.
Article
23. Casey DE, Laubmeier KK, Eudicone JM, Marcus R, Berman RM, Rahman Z, et al. Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy. Int J Clin Pract. 2014; 68:1301–1308.
Article
24. Stewart TD, Hatch A, Largay K, Sheehan JJ, Marler SV, Berman RM, et al. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis. J Affect Disord. 2014; 162:20–25.
Article
25. Nelson JC, Rahman Z, Laubmeier KK, Eudicone JM, McQuade RD, Berman RM, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy. CNS Spectr. 2014; 19:528–534.
Article
26. Han C, Wang SM, Lee SJ, Jun TY, Pae CU. Optimizing the use of aripiprazole augmentation in the treatment of major depressive disorder: from clinical trials to clinical practice. Chonnam Med J. 2015; 51:66–80.
Article
27. Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, et al. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). J Affect Disord. 2013; 151:899–905.
Article
28. Ozaki N, Otsubo T, Kato M, Higuchi T, Ono H, Kamijima K. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of theAripiprazole Depression Multicenter Efficacy study. Psychiatry Clin Neurosci. 2015; 69:34–42.
Article
29. Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015; 386:2404–2412.
Article
30. Han C, Wang SM, Kwak KP, Won WY, Lee H, Chang CM, et al. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study. J Psychiatr Res. 2015; 66-67:84–94.
Article
31. Han C, Wang SM, Seo HJ, Lee BC, Jeon HJ, Kim W, et al. Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: a multi-center, naturalistic study. J Psychiatr Res. 2014; 49:75–82.
Article
32. Bortnick B, El-Khalili N, Banov M, Adson D, Datto C, Raines S, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord. 2011; 128:83–94.
Article
33. Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 2010; 27:964–976.
Article
34. Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2012; 27:27–39.
Article
35. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009; 70:526–539.
Article
36. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010; 13:917–932.
Article
37. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009; 70:540–549.
Article
38. Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol. 2008; 23:269–275.
Article
39. Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry. 2008; 8:73.
Article
40. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007; 24:487–494.
Article
41. Wijkstra J, Burger H, van den Broek WW, Birkenhäger TK, Janzing JG, Boks MP, et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand. 2010; 121:190–200.
Article
42. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009; 14:299–313.
Article
43. Locklear JC, Svedsäter H, Datto C, Endicott J. Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder. J Affect Disord. 2013; 149:189–195.
Article
44. McIntyre A, Paisley D, Kouassi E, Gendron A. Quetiapine fumarate extended-release for the treatment of major depression with comorbid fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. Arthritis Rheumatol. 2014; 66:451–461.
Article
45. Wang G, McIntyre A, Earley WR, Raines SR, Eriksson H. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2014; 10:201–216.
Article
46. Bauer M, Thase ME, Liu S, Earley W, Eriksson H. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder. J Psychopharmacol. 2015; 29:565–574.
Article
47. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005; 66:1289–1297.
48. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006; 23:364–372.
Article
49. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007; 68:224–236.
Article
50. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004; 24:365–373.
Article
51. Meyers BS, Flint AJ, Rothschild AJ, Mulsant BH, Whyte EM, Peasley-Miklus C, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry. 2009; 66:838–847.
Article
52. Brunner E, Tohen M, Osuntokun O, Landry J, Thase ME. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology. 2014; 39:2549–2559.
Article
53. Rocca P, Marchiaro L, Rasetti R, Rivoira E, Bogetto F. A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. Psychiatry Res. 2002; 112:145–152.
Article
54. Rocca P, Fonzo V, Ravizza L, Rocca G, Scotta M, Zanalda E, et al. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Disord. 2002; 70:313–317.
Article
55. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol. 2006; 16:281–287.
Article
56. Cassano GB, Jori MC. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol. 2002; 17:27–32.
Article
57. Ravizza L. Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators. J Psychopharmacol. 1999; 13:248–254.
Article
58. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology. 1999; 39:25–32.
Article
59. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord. 1998; 48:47–56.
Article
60. Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord. 1997; 43:95–103.
Article
61. León CA, Vigoya J, Conde S, Campo G, Castrillón E, León A. Comparison of the effect of amisulpride and viloxazine in the treatment of dysthymia. Acta Psiquiatr Psicol Am Lat. 1994; 40:41–49.
62. Amore M, Jori MC. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol. 2001; 16:317–324.
Article
63. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007; 147:593–602.
Article
64. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res. 2009; 43:205–214.
Article
65. Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008; 69:1228–1336.
66. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology. 2006; 31:2505–2513.
Article
67. Alexopoulos GS, Canuso CM, Gharabawi GM, Bossie CA, Greenspan A, Turkoz I, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry. 2008; 16:21–30.
Article
68. Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, et al. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry. 2012; 73:1541–1547.
Article
69. Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, et al. Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial. Int Clin Psychopharmacol. 2014; 29:332–338.
Article
70. Heo JY, Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, et al. Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial. J Psychiatr Res. 2015; 62:56–61.
Article
71. Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, et al. Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results from a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2015; 172:1251–1258.
Article
72. McCormack PL. Cariprazine: first global approval. Drugs. 2015; 75:2035–2043.
Article
73. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013; 9:193–206.
Article
74. Yang FW, Liang CS. Paliperidone augmentation for treatment-resistant depression: a case report. J Clin Psychopharmacol. 2011; 31:245–246.
75. Suppes T, Silva R, Cucchiaro J, Mao Y, Targum S, Streicher C, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016; 173:400–407.
Article
76. Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G. Off-label indications for atypical antipsychotics: a systematic review. Ann Gen Hosp Psychiatry. 2004; 3:4.
77. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007; 68:826–831.
Article
78. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009; 166:980–991.
Article
79. Pae CU. Why Systematic review rather than narrative review? Psychiatry Investig. 2015; 12:417–419.
Article
80. Arbaizar B, Dierssen-Sotos T, Gómez-Acebo I, Llorca J. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. Gen Hosp Psychiatry. 2009; 31:478–483.
Article
81. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. 2012; 12:160.
Article
82. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013; 10:e1001403.
Article
83. Wen XJ, Wang LM, Liu ZL, Huang A, Liu YY, Hu JY. Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder. Braz J Med Biol Res. 2014; 47:605–616.
Article
84. Shelton RC. What are the comparative benefits and harms of augmentation treatments in major depression? J Clin Psychiatry. 2015; 76:e531–e533.
Article
85. Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015; 76:e487–e498.
86. Zhou X, Keitner GI, Qin B, Ravindran AV, Bauer M, Del Giovane C, et al. Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol. 2015; 18:DOI: 10.1093/ijnp/pyv060.
Article
87. Wang HR, Woo YS, Ahn HS, Ahn IM, Kim HJ, Bahk WM. Can atypical antipsychotic augmentation reduce subsequent treatment failure more effectively among depressed patients with a higher degree of treatment resistance? A meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2015; 18:DOI: 10.1093/ijnp/pyv023.
Article
88. Quante A, Regen F, Schindler F, Volkmer K, Severus E, Urbanek C, et al. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study. Psychiatr Danub. 2013; 25:214–220.
Full Text Links
  • CMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr